These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 26946483)

  • 1. Innate immunity regulates α-synuclein clearance.
    Sawamura M; Uemura N; Takahashi R
    Mov Disord; 2016 May; 31(5):638. PubMed ID: 26946483
    [No Abstract]   [Full Text] [Related]  

  • 2. Another Brick in the Wall.
    Herwald H; Egesten A
    J Innate Immun; 2019; 11(2):109-110. PubMed ID: 30808848
    [No Abstract]   [Full Text] [Related]  

  • 3. Immune receptor for pathogenic α-synuclein.
    Jucker M; Heikenwalder M
    Science; 2016 Sep; 353(6307):1498-1499. PubMed ID: 27708090
    [No Abstract]   [Full Text] [Related]  

  • 4. A Role for Neuronal Alpha-Synuclein in Gastrointestinal Immunity.
    Stolzenberg E; Berry D; Yang D; Lee EY; Kroemer A; Kaufman S; Wong GCL; Oppenheim JJ; Sen S; Fishbein T; Bax A; Harris B; Barbut D; Zasloff MA
    J Innate Immun; 2017; 9(5):456-463. PubMed ID: 28651250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sticking it to Parkinson's disease.
    Leslie M
    Sci Aging Knowledge Environ; 2005 Jun; 2005(25):nf46. PubMed ID: 15975896
    [No Abstract]   [Full Text] [Related]  

  • 6. Immunologic treatment of Parkinson's disease.
    Jankovic J
    Immunotherapy; 2018 Feb; 10(2):81-84. PubMed ID: 29260621
    [No Abstract]   [Full Text] [Related]  

  • 7. Immunotherapy targeting α-synuclein, with relevance for future treatment of Parkinson's disease and other Lewy body disorders.
    Lindström V; Ihse E; Fagerqvist T; Bergström J; Nordström E; Möller C; Lannfelt L; Ingelsson M
    Immunotherapy; 2014; 6(2):141-53. PubMed ID: 24491088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunomodulation as a neuroprotective and therapeutic strategy for Parkinson's disease.
    Olson KE; Gendelman HE
    Curr Opin Pharmacol; 2016 Feb; 26():87-95. PubMed ID: 26571205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Linking Neuroinflammation and Neurodegeneration in Parkinson's Disease.
    Gelders G; Baekelandt V; Van der Perren A
    J Immunol Res; 2018; 2018():4784268. PubMed ID: 29850629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunochemical Detection of α-Synuclein Autoantibodies in Parkinson's Disease: Correlation between Plasma and Cerebrospinal Fluid Levels.
    Horvath I; Iashchishyn IA; Forsgren L; Morozova-Roche LA
    ACS Chem Neurosci; 2017 Jun; 8(6):1170-1176. PubMed ID: 28263550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Naturally occurring α-synuclein autoantibody levels are lower in patients with Parkinson disease.
    Besong-Agbo D; Wolf E; Jessen F; Oechsner M; Hametner E; Poewe W; Reindl M; Oertel WH; Noelker C; Bacher M; Dodel R
    Neurology; 2013 Jan; 80(2):169-75. PubMed ID: 23255825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Naturally occurring alpha-synuclein autoantibodies in Parkinson's disease: sources of (error) variance in biomarker assays.
    Heinzel S; Gold M; Deuschle C; Bernhard F; Maetzler W; Berg D; Dodel R
    PLoS One; 2014; 9(12):e114566. PubMed ID: 25470145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. α-Synuclein vaccination prevents the accumulation of parkinson disease-like pathologic inclusions in striatum in association with regulatory T cell recruitment in a rat model.
    Sanchez-Guajardo V; Annibali A; Jensen PH; Romero-Ramos M
    J Neuropathol Exp Neurol; 2013 Jul; 72(7):624-45. PubMed ID: 23771222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First therapy targeting Parkinson's proteins enters clinical trials.
    Dolgin E
    Nat Med; 2012 Jul; 18(7):992-3. PubMed ID: 22772533
    [No Abstract]   [Full Text] [Related]  

  • 15. Enzyme-linked immunosorbent assays for α-synuclein with species and multimeric state specificities.
    Lee HJ; Bae EJ; Jang A; Ho DH; Cho ED; Suk JE; Yun YM; Lee SJ
    J Neurosci Methods; 2011 Aug; 199(2):249-57. PubMed ID: 21658411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunoprotection against toxic biomarkers is retained during Parkinson's disease progression.
    Gruden MA; Sewell RD; Yanamandra K; Davidova TV; Kucheryanu VG; Bocharov EV; Bocharova OA; Polyschuk VV; Sherstnev VV; Morozova-Roche LA
    J Neuroimmunol; 2011 Apr; 233(1-2):221-7. PubMed ID: 21239064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alpha-synuclein, Parkinson's disease, and Alzheimer's disease.
    Kim S; Seo JH; Suh YH
    Parkinsonism Relat Disord; 2004 May; 10 Suppl 1():S9-13. PubMed ID: 15109581
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of Passive Immunotherapies for Synucleinopathies.
    Bergström AL; Kallunki P; Fog K
    Mov Disord; 2016 Feb; 31(2):203-13. PubMed ID: 26704735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intrabody and Parkinson's disease.
    Zhou C; Przedborski S
    Biochim Biophys Acta; 2009 Jul; 1792(7):634-42. PubMed ID: 18834937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccination strategies for Parkinson disease: induction of a swift attack or raising tolerance?
    Romero-Ramos M; von Euler Chelpin M; Sanchez-Guajardo V
    Hum Vaccin Immunother; 2014; 10(4):852-67. PubMed ID: 24670306
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.